Alnylam Pharmaceuticals Inc (ALNY)vsWheaton Precious Metals Corp (WPM)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
WPM
Wheaton Precious Metals Corp
$122.64
+1.70%
BASIC MATERIALS · Cap: $54.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 60% more annual revenue ($3.71B vs $2.31B). WPM leads profitability with a 63.6% profit margin vs 8.5%. WPM trades at a lower P/E of 37.3x. WPM earns a higher WallStSmart Score of 76/100 (B+).
ALNY
Hold49
out of 100
Grade: D+
WPM
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Margin of Safety
+1.4%
Fair Value
$151.16
Current Price
$122.64
$28.52 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Growing faster than its price suggests
Keeps 64 of every $100 in revenue as profit
Strong operational efficiency at 75.2%
Revenue surging 127.2% year-over-year
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : WPM
The strongest argument for WPM centers on PEG Ratio, Profit Margin, Operating Margin. Profitability is solid with margins at 63.6% and operating margin at 75.2%. Revenue growth of 127.2% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : WPM
The primary concerns for WPM are P/E Ratio.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while WPM is a growth play — different risk/reward profiles.
WPM carries more volatility with a beta of 1.11 — expect wider price swings.
WPM is growing revenue faster at 127.2% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
WPM scores higher overall (76/100 vs 49/100), backed by strong 63.6% margins and 127.2% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Wheaton Precious Metals Corp
BASIC MATERIALS · GOLD · USA
Wheaton Precious Metals Corp. The company is headquartered in Vancouver, Canada.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?